our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
TOP2A amplification
i
Other names: TOP2A, DNA Topoisomerase II Alpha, Topoisomerase (DNA) II Alpha 170kDa, DNA Topoisomerase II, Alpha Isozyme, DNA Topoisomerase 2-Alpha, TOP2, DNA Topoisomerase II, 170 KD
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
The increased expression of TOP2A is associated with poor clinical outcomes, indicating its potential as a valuable biomarker for assessing risk and stratifying treatment in these malignancies. However, further investigation is needed to elucidate the underlying mechanisms by which TOP2A influences cancer progression and to explore its potential as a therapeutic target.
Our results showed high pCR rates with Trastuzumab and Pertuzumab associated to chemotherapy. They were similar in TOP2A + and TOP2A- groups and the current role of neoadjuvant anthracycline-based chemotherapy remains questioned.
HER-2 and TOP2A genes amplification are 2 separate genetic yet closely related events in breast cancer. Polysomy of chromosome 17 is proposed to be an early event in occurrence of TOP2A gene amplification. Further studies regarding effect of TOP2A gene in response to anthracyclines in Egyptian population should be planned for to establish its role in therapeutic planning.